ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor receptor‐tyrosine kinase inhibitor, enhances the anti‐cancer effects of TRAIL in human esophageal squamous cell carcinoma
Fuminori Teraishi(Okayama University), Toshiyoshi Fujiwara(Okayama University)
Cited by 64
Related Papers
The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer
|Journal of Experimental & Clinical Cancer Research|2018|111
Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody
|Molecular Therapy|2020|77
Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma
|Cancer Biology & Therapy|2019|76
Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer
|Scientific Reports|2021|75
A Genetically Engineered Oncolytic Adenovirus Decoys and Lethally Traps Quiescent Cancer Stem–like Cells in S/G2/M Phases
|Clinical Cancer Research|2013|74